A Phase 3 interventional study of Estradiol/Norethindrone Acetate and Placebo for Elagolix in Endometriosis, sponsored by AbbVie. Completed at 197 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Endometriosis by AbbVie — none open to participants now, 1 under way, 1 of them phase 3. Endometriosis · AbbVie.
Among the 21 studies in Endometriosis by AbbVie, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 15th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 21 studies in Endometriosis by AbbVie is open now. The open studies under Endometriosis, anywhere →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 681 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 195 across the 16 interventional studies, 173 across the 5 observational. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
1 of the studies in Endometriosis by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Endometriosis by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants including the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must have the following documented in the e-Diary during the last 35 days prior to Study Day 1:
Exclusion Criteria:
Participant has either:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
Drug: Placebo for Elagolix · Drug: Placebo for E2/NETA
Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
Drug: Estradiol/Norethindrone Acetate · Drug: Elagolix
Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
Drug: Estradiol/Norethindrone Acetate · Drug: Elagolix
Drug pages: Estradiol · Norethindrone Acetate
Tablets
Also known as: Activella, E2/NETA
Tablet
Tablet
Also known as: ABT-620, Elagolix Sodium, ORILISSA
Tablets
Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment
Participants recorded rescue analgesic use for endometriosis-associated pain daily and DYS (pain during menstruation ) and its impact on daily activities each day of their period in an electronic diary (e-Diary). DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over 35 days prior to each visit. Response was defined as a reduction of -0.92 or more from baseline in DYS as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average rescue analgesic pill count and no additional analgesic).
Time frame: Month 6, Month 12
Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit. Response was defined as a reduction of -0.55 or greater from baseline for NMPP as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average pill count of rescue analgesics and no additional analgesics).
Time frame: Month 6, Month 12
Change From Baseline in DYS at Month 12 Based on Daily Assessment
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 12
Change From Baseline in DYS at Month 6 Based on Daily Assessment
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 6
Change From Baseline in DYS at Month 3 Based on Daily Assessment
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 3
Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 12
Change From Baseline in NMPP at Month 6 Based on Daily Assessment
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 6
Change From Baseline in NMPP at Month 3 Based on Daily Assessment
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 3
Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.
Time frame: Baseline, Month 6
Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
Time frame: Baseline, Month 12
Change From Baseline in DYSP at Month 6 Based on Daily Assessment
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
Time frame: Baseline, Month 6
Change From Baseline in DYSP at Month 3 Based on Daily Assessment
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
Time frame: Baseline, Month 3
Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.
Time frame: Baseline, Month 12
Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS)
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 12
Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 6
Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
Time frame: Baseline, Month 3
A total of 679 subjects were treated at 137 sites in 2 countries (US \[including Puerto Rico\] and Canada). Of the 679 subjects who were treated on study, 299 subjects discontinued study drug prematurely during the Placebo-Controlled Treatment Period and 240 discontinued study drug prematurely during the Open-Label Treatment Period.
| Milestone | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 194 | 98 | 389 |
| Completed | 193 | 97 | 389 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 0 |
| Milestone | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 193 | 97 | 389 |
| Completed | 157 | 85 | 337 |
| Not completed | 36 | 12 | 52 |
| Withdrew: Adverse event | 3 | 2 | 7 |
| Withdrew: Withdrawal by subject | 14 | 2 | 14 |
| Withdrew: Lost to follow-up | 2 | 3 | 9 |
| Withdrew: Requires surgery or invasive intervention for treatment of endometriosis | 2 | 0 | 1 |
| Withdrew: Non-compliance with study procedures | 0 | 2 | 4 |
| Withdrew: Pregnancy | 5 | 0 | 0 |
| Withdrew: Other | 10 | 3 | 17 |
| Milestone | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 106 | 59 | 215 |
| Completed | 90 | 48 | 170 |
| Not completed | 16 | 11 | 45 |
| Withdrew: Adverse event | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 12 | 5 | 24 |
| Withdrew: Lost to follow-up | 1 | 2 | 8 |
| Withdrew: Requires surgery or invasive intervention for treatment of endometriosis | 0 | 0 | 2 |
| Withdrew: Non-compliance with study procedures | 1 | 1 | 2 |
| Withdrew: Exclusionary medications | 0 | 0 | 1 |
| Withdrew: Other | 1 | 1 | 6 |
| Milestone | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA |
|---|---|---|---|
| Started | 194 | 98 | 389 |
| Completed | 102 | 51 | 185 |
| Not completed | 92 | 47 | 204 |
| Withdrew: Adverse event | 16 | 8 | 37 |
| Withdrew: Withdrawal by subject | 18 | 11 | 55 |
| Withdrew: Lost to follow-up | 28 | 15 | 50 |
| Withdrew: Requires surgery or invasive intervention for treatment of endometriosis | 3 | 1 | 2 |
| Withdrew: Non-compliance with study procedures | 4 | 1 | 6 |
| Withdrew: Pregnancy | 7 | 0 | 18 |
| Withdrew: Exclusionary medications | 1 | 1 | 5 |
| Withdrew: Covid-19 logistical restrictions | 1 | 0 | 0 |
| Withdrew: Other | 14 | 10 | 31 |
Participants recorded rescue analgesic use for endometriosis-associated pain daily and DYS (pain during menstruation ) and its impact on daily activities each day of their period in an electronic diary (e-Diary). DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over 35 days prior to each visit. Response was defined as a reduction of -0.92 or more from baseline in DYS as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average rescue analgesic pill count and no additional analgesic).
| percentage of participants | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Month 6 | 23.7 (17.64 to 29.73) | 62.8 (57.93 to 67.60) |
| Month 12 | 29.1 (22.62 to 35.58) | 63.8 (58.97 to 68.69) |
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit. Response was defined as a reduction of -0.55 or greater from baseline for NMPP as well as no increase in rescue analgesic use for endometriosis-associated pain (defined as a \< 15% increase in average pill count of rescue analgesics and no additional analgesics).
| percentage of participants | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Month 6 | 36.8 (29.98 to 43.70) | 51.3 (46.30 to 56.30) |
| Month 12 | 42.3 (35.28 to 49.37) | 54.3 (49.22 to 59.29) |
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in DYS at Month 12 Based on Daily Assessment | -0.73 ± 0.077 | -1.73 ± 0.055 |
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in DYS at Month 6 Based on Daily Assessment | -0.62 ± 0.072 | -1.64 ± 0.050 |
Participants assessed DYS (pain during menstruation) and its impact on their daily activities each day of their period in an e-Diary. DYS was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: 0: No discomfort 1. Mild discomfort but I was easily able to do the things I usually do 2. Moderate discomfort or pain that made it difficult to do some of the things I usually do 3. Severe pain that made it difficult to do the things I usually do. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in DYS at Month 3 Based on Daily Assessment | -0.56 ± 0.069 | -1.54 ± 0.049 |
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment | -0.64 ± 0.060 | -0.86 ± 0.042 |
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in NMPP at Month 6 Based on Daily Assessment | -0.57 ± 0.051 | -0.78 ± 0.036 |
Participants recorded rescue analgesic medication for endometriosis-associated pain and assessed NMPP and its impact on their daily activities each day in an e-Diary was measured by the 4-point Endometriosis Daily Pain Impact Diary according to the following: * 0: No discomfort * 1: Mild discomfort but I was easily able to do the things I usually do * 2: Moderate discomfort or pain that made it difficult to do some of the things I usually do * 3: Severe pain that made it difficult to do the things I usually do. Pain scores and analgesic use were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in NMPP at Month 3 Based on Daily Assessment | -0.49 ± 0.046 | -0.65 ± 0.032 |
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.
| T-score | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline to Month 6 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score | -4.71 ± 0.739 | -7.22 ± 0.514 |
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in Dyspareunia (DYSP) at Month 12 Based on Daily Assessment | -0.60 ± 0.079 | -0.70 ± 0.058 |
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in DYSP at Month 6 Based on Daily Assessment | -0.54 ± 0.076 | -0.63 ± 0.053 |
Participants assessed DYSP each day in an e-Diary according to the following response options: * 0: None; No discomfort during sexual intercourse * 1: Mild; Able to tolerate the discomfort during sexual intercourse * 2: Moderate; Intercourse was interrupted due to pain * 3: Severe; Avoided intercourse because of pain * Not applicable; I was not sexually active for reasons other than endometriosis or did not have sexual intercourse. Pain scores were averaged over the 35 days prior to each visit. Responses of "Not Applicable" were excluded.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in DYSP at Month 3 Based on Daily Assessment | -0.40 ± 0.064 | -0.62 ± 0.045 |
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue over the past 7 days. All questions employ the following five response options: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, and 5 = Always. The PROMIS Fatigue 6a score is calculated as a T-score, which is a standardized score with a mean of 50 (based on the average for the United States general population) and a standard deviation (SD) of 10. Higher scores indicate higher levels of fatigue. A decrease in score (negative change from baseline) indicates improvement in fatigue.
| T-score | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline to Month 12 in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 6a T-Score | -6.43 ± 0.949 | -8.92 ± 0.665 |
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in Endometriosis-Associated Pain Score at Month 12 Assessed With Numeric Rating Scale (NRS) | -3.25 ± 0.263 | -4.39 ± 0.186 |
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in Endometriosis-Associated Pain Score at Month 6 Assessed With NRS | -2.74 ± 0.248 | -4.12 ± 0.174 |
The NRS measured endometriosis-associated pain with and without menstruation on an 11-point scale from 0 = no pain to 10 = worst pain ever. Site staff administered the Overall Endometriosis-Associated Pain questionnaire assessing pain over a 7-day recall period, and recorded the participant's response electronically via a tablet at the time of visit. Pain scores were averaged over the 35 days prior to each visit.
| score on a scale | Placebo | Elagolix + E2/NETA |
|---|---|---|
| Change From Baseline in Endometriosis-Associated Pain Score at Month 3 Assessed With NRS | -2.33 ± 0.225 | -3.79 ± 0.161 |
Collected over All-cause mortality: from randomization through the end of the Treatment Period (Month 12). Adverse Events(AEs): From first dose of study drug through the end of the Treatment Period (Month 12).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SCR_Placebo | 0/194 (0%) | 0/194 (0%) | 1/194 (0.5%) |
| SCR_Elagolix | 0/98 (0%) | 0/98 (0%) | 0/98 (0%) |
| SCR_Elagolix_and_E2-NETA | 0/389 (0%) | 1/389 (0.3%) | 1/389 (0.3%) |
| DB_Placebo | 0/194 (0%) | 8/194 (4.1%) | 89/194 (45.9%) |
| DB_Elagolix | 0/98 (0%) | 2/98 (2%) | 74/98 (75.5%) |
| DB_Elagolix_and_E2-NETA | 0/389 (0%) | 14/389 (3.6%) | 236/389 (60.7%) |
| OL_Placebo_to_ELA_and_E2-NETA | 0/106 (0%) | 7/106 (6.6%) | 60/106 (56.6%) |
| OL_ELA_to_ELA_and_E2-NETA | 0/59 (0%) | 2/59 (3.4%) | 32/59 (54.2%) |
| OL_ELA_and_E2-NETA_to_ELA_and_E2-NETA | 0/215 (0%) | 10/215 (4.7%) | 125/215 (58.1%) |
| FU_Placebo_to_ELA_and_E2-NETA | 0/194 (0%) | 2/194 (1%) | 2/194 (1%) |
| FU_ELA_to_ELA_and_E2-NETA | 0/98 (0%) | 0/98 (0%) | 3/98 (3.1%) |
| FU_ELA_and_E2-NETA_to_ELA_and_E2-NETA | 0/389 (0%) | 1/389 (0.3%) | 6/389 (1.5%) |
| Event | SCR_Placebo | SCR_Elagolix | SCR_Elagolix_and_E2-NETA | DB_Placebo | DB_Elagolix | DB_Elagolix_and_E2-NETA | OL_Placebo_to_ELA_and_E2-NETA | OL_ELA_to_ELA_and_E2-NETA | OL_ELA_and_E2-NETA_to_ELA_and_E2-NETA | FU_Placebo_to_ELA_and_E2-NETA | FU_ELA_to_ELA_and_E2-NETA | FU_ELA_and_E2-NETA_to_ELA_and_E2-NETA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABDOMINAL PAIN LOWERGastrointestinal disorders | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 0/106 | 1/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| NAUSEAGastrointestinal disorders | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 0/106 | 1/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| OVARIAN CYST RUPTUREDReproductive system and breast disorders | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 0/106 | 1/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| ENDOMETRIOSISReproductive system and breast disorders | 0/194 | 0/98 | 0/389 | 2/194 | 1/98 | 0/389 | 0/106 | 0/59 | 1/215 | 0/194 | 0/98 | 0/389 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 0/194 | 0/98 | 0/389 | 0/194 | 1/98 | 0/389 | 0/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| ABSCESS INTESTINALInfections and infestations | 0/194 | 0/98 | 0/389 | 0/194 | 1/98 | 0/389 | 0/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| FOOD POISONINGGastrointestinal disorders | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 1/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| APPENDICITISInfections and infestations | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 1/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| GASTROENTERITISInfections and infestations | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 1/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| FLANK PAINMusculoskeletal and connective tissue disorders | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 1/106 | 0/59 | 0/215 | 0/194 | 0/98 | 0/389 |
| Event | SCR_Placebo | SCR_Elagolix | SCR_Elagolix_and_E2-NETA | DB_Placebo | DB_Elagolix | DB_Elagolix_and_E2-NETA | OL_Placebo_to_ELA_and_E2-NETA | OL_ELA_to_ELA_and_E2-NETA | OL_ELA_and_E2-NETA_to_ELA_and_E2-NETA | FU_Placebo_to_ELA_and_E2-NETA | FU_ELA_to_ELA_and_E2-NETA | FU_ELA_and_E2-NETA_to_ELA_and_E2-NETA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HOT FLUSHVascular disorders | 0/194 | 0/98 | 0/389 | 14/194 | 43/98 | 69/389 | 8/106 | 2/59 | 10/215 | 0/194 | 0/98 | 0/389 |
| NAUSEAGastrointestinal disorders | 1/194 | 0/98 | 0/389 | 12/194 | 16/98 | 51/389 | 9/106 | 2/59 | 12/215 | 0/194 | 0/98 | 1/389 |
| COVID-19Infections and infestations | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 0/389 | 9/106 | 7/59 | 29/215 | 1/194 | 0/98 | 2/389 |
| HEADACHENervous system disorders | 1/194 | 0/98 | 0/389 | 10/194 | 13/98 | 46/389 | 8/106 | 4/59 | 7/215 | 0/194 | 0/98 | 1/389 |
| NIGHT SWEATSSkin and subcutaneous tissue disorders | 0/194 | 0/98 | 0/389 | 6/194 | 13/98 | 24/389 | 3/106 | 0/59 | 5/215 | 0/194 | 0/98 | 0/389 |
| SINUSITISInfections and infestations | 0/194 | 0/98 | 0/389 | 13/194 | 10/98 | 32/389 | 9/106 | 5/59 | 18/215 | 0/194 | 1/98 | 0/389 |
| BRONCHITISInfections and infestations | 0/194 | 0/98 | 0/389 | 6/194 | 3/98 | 11/389 | 5/106 | 6/59 | 9/215 | 0/194 | 0/98 | 0/389 |
| BONE DENSITY DECREASEDInvestigations | 0/194 | 0/98 | 0/389 | 0/194 | 0/98 | 5/389 | 7/106 | 6/59 | 21/215 | 0/194 | 1/98 | 1/389 |
| URINARY TRACT INFECTIONInfections and infestations | 0/194 | 0/98 | 0/389 | 9/194 | 9/98 | 15/389 | 6/106 | 5/59 | 16/215 | 1/194 | 1/98 | 0/389 |
| INSOMNIAPsychiatric disorders | 0/194 | 0/98 | 0/389 | 1/194 | 9/98 | 13/389 | 5/106 | 1/59 | 6/215 | 0/194 | 0/98 | 1/389 |
Full Analysis Set: all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Mean | 33.1 ± 6.72 | 32.5 ± 6.44 | 32.3 ± 6.74 | 32.5 ± 6.69 |
| Sex/Gender, Customized(Participants) | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Female | 193 | 97 | 389 | 679 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| Hispanic or Latino | 37 | 11 | 58 | 106 |
| Not Hispanic or Latino | 156 | 86 | 331 | 573 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Elagolix / Elagolix + E2/NETA | Elagolix + E2/NETA | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 0 | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 31 | 19 | 49 | 99 |
| White | 159 | 74 | 328 | 561 |
| More than one race | 2 | 4 | 6 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 197 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jul 2017 to primary completion in Mar 2020, 32 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Norethindrone Acetate · Elagolix